Clinical Significance of Monosomal Karyotype in MDS.
10.19746/j.cnki.issn.1009-2137.2019.03.036
- Author:
Shan-Shan GUO
1
;
Pan-Pan GAO
2
;
Qi-Tian MU
3
;
Gui-Fang OUYANG
4
Author Information
1. Zhejiang University School of Medicine, Hangzhou 310029, Zhejiang Province, China.
2. Ningbo University School of Medicine, Ningbo 315211, Zhejiang Province, China.
3. Laboratory of Stem Cell Transplantation, Ningbo Hospital of Zhejiang University, Ningbo 315000, Zhejiang Province, China.
4. Department of Hematology, Ningbo Hospital of Zhejiang University, Ningbo 315000, Zhejiang Province, China,E-mail:nbougf@163.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Karyotype;
Karyotyping;
Monosomy;
Myelodysplastic Syndromes;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2019;27(3):860-866
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the frequency, karyotype characteristics and prognosis significance of monosomal karyotype (MK) in newly diagnosed MDS patients.
METHODS:The clinical, laboratorial and follow-up data of 202 MDS patients received the chromosome karyotype test in Department of Hematology, Ningbo Hospital of Zhejiang University from 2009 to 2018 were analyzed retrospectively, the monosomal karyotype features, clinical characteristics and their effects on the prognosis of MDS patients also were analyzed.
RESULTS:Among 202 cases of MDS, 25 (12.38%) confirmed to be the MK. The abnormality of chromosome 5 (60.00%), 7 (56.00%), 17 (56.00%), 15 (56.00%), 13 (40.00%) and 20（40.00%）were common in monosomal karyotype. MK-MDS (MDS with monosomal karyotype) patients had higher bone marrow blast percentage than MK-MDS (MDS without monosomal karyotype) patients, the median are 6.25% and 3.00% (P＜0.01) respectively, but there were no difference in age, sex, hemoglobin level, white blood cell count, neutrophile granulocyte percentage, platelet count, blood blast percentage, serum ferritin, folic acid and vitaminB12 between MK-MDS and MK-MDS. The overall survival time of MK-MDS and MK-MDS patiens with chromosome 3, 5, 7, 13, 15, 17 abnormalities was significantly shorter than MK-MDS and AK+MK-MDS patients (MDS with abnormal karyotype but without monosomal karyotype) , the MK-MDS patients had a median survival time of 7.33 months, but the median survival time had not been reached in MK-MDS and AK+MK-MDS patients had not been reached by the end of the follow-up, and could not be assessed (P＜0.01).
CONCLUSION:The monosomal karyotype is a poor prognosis factor for newly-diagnosed MDS patients. The poor prognosis suggested by monosomal karyotype may be related with the abnormality of 3, 5, 7, 13, 15 and 17 chromosome.
